BR112012020481A2 - método para tratar um paciente, o método compreendendo administrar uma formulação farmacêutica contendo uma quantidade fisiologicamente efetiva de um análogo de insulina ou um sal fisiologicamente. - Google Patents
método para tratar um paciente, o método compreendendo administrar uma formulação farmacêutica contendo uma quantidade fisiologicamente efetiva de um análogo de insulina ou um sal fisiologicamente.Info
- Publication number
- BR112012020481A2 BR112012020481A2 BR112012020481A BR112012020481A BR112012020481A2 BR 112012020481 A2 BR112012020481 A2 BR 112012020481A2 BR 112012020481 A BR112012020481 A BR 112012020481A BR 112012020481 A BR112012020481 A BR 112012020481A BR 112012020481 A2 BR112012020481 A2 BR 112012020481A2
- Authority
- BR
- Brazil
- Prior art keywords
- insulin
- formulation
- physiologically
- pharmaceutical formulation
- patient
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 14
- 239000004026 insulin derivative Substances 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 102000004877 Insulin Human genes 0.000 abstract 3
- 108090001061 Insulin Proteins 0.000 abstract 3
- 229940125396 insulin Drugs 0.000 abstract 3
- 238000006467 substitution reaction Methods 0.000 abstract 3
- 102000003746 Insulin Receptor Human genes 0.000 abstract 1
- 108010001127 Insulin Receptor Proteins 0.000 abstract 1
- 102000004584 Somatomedin Receptors Human genes 0.000 abstract 1
- 108010017622 Somatomedin Receptors Proteins 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
- 238000010254 subcutaneous injection Methods 0.000 abstract 1
- 239000007929 subcutaneous injection Substances 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
método para tratar um paciente, o método compreendendo administrar um formulação farmacêutica contendo uma quantidade fisiologicamente efetiva de um análogo de insulina ou um sal fisiologicamente aceitável deste ao paciente, ácido nucleíco codificando um polipeptídeo de cadeia a de insulina, vetor de expressão, célula hospedeira, formulação farmacêutica compreendendo um análogo de insulina ou um sal fisiologicamente aceitável deste, formulação cristalina de um análogo de insulina. uma formulação farmacêutica compreende um análogo de insulina ou um sal fisiologicamente aceitável deste contém uma sequência de cadeia a de insulina que contém substituições de histidina emparelhadas em a4 e a8, e opcionalmente uma substituição em a21. a formulação contém, adicionalmente, um tampão farmaceuticamente aceitável contendo pelo menos cerca de 4 íons de zinco por 6 moléculas de análogo de insulina. a formulação forma um depósito subcutâneo dependente de zinco de longa atuação mediante injeção subcutânea. em uma formulação livre de zinco, o monômero de análogo de insulina apresenta afinidade diminuída para o receptor do fator de crescimento de insulina-símile e em pelo menos 20% da afinidade para o receptor de insulina das mesmas espécies em comparação com uma insulina idêntica diferente ou análogo de insulina que não contém as substituições his^ a4^ e his^ a8^.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30672210P | 2010-02-22 | 2010-02-22 | |
| PCT/US2011/025730 WO2011103575A1 (en) | 2010-02-22 | 2011-02-22 | Long-acting insulin analogue preparations in soluble and crystalline forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012020481A2 true BR112012020481A2 (pt) | 2017-01-10 |
Family
ID=44483357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012020481A BR112012020481A2 (pt) | 2010-02-22 | 2011-02-22 | método para tratar um paciente, o método compreendendo administrar uma formulação farmacêutica contendo uma quantidade fisiologicamente efetiva de um análogo de insulina ou um sal fisiologicamente. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20130085101A1 (pt) |
| EP (1) | EP2538966A4 (pt) |
| JP (1) | JP2013520175A (pt) |
| KR (1) | KR20130043085A (pt) |
| CN (1) | CN102770153B (pt) |
| AU (1) | AU2011217761A1 (pt) |
| BR (1) | BR112012020481A2 (pt) |
| CA (1) | CA2790495A1 (pt) |
| EA (1) | EA201201164A1 (pt) |
| HK (1) | HK1178444A1 (pt) |
| MX (1) | MX2012009618A (pt) |
| SG (1) | SG183106A1 (pt) |
| WO (1) | WO2011103575A1 (pt) |
| ZA (1) | ZA201205315B (pt) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2074140B8 (en) | 2006-10-04 | 2015-10-28 | Case Western Reserve University | Fibrillation-resistant insulin and insulin analogues |
| US8993516B2 (en) | 2008-04-14 | 2015-03-31 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
| US9200053B2 (en) | 2008-07-31 | 2015-12-01 | Case Western Reserve University | Insulin analogues containing penta-fluoro-Phenylalanine at position B24 |
| KR20120129875A (ko) | 2008-07-31 | 2012-11-28 | 케이스 웨스턴 리저브 유니버시티 | 염소화 아미노산을 갖는 인슐린 유사체 |
| HUE037449T2 (hu) | 2008-10-17 | 2018-08-28 | Sanofi Aventis Deutschland | Egy inzulin és egy GLP-1 agonista kombinációja |
| US8399407B2 (en) | 2009-09-17 | 2013-03-19 | Case Western Reserve University | Non-standard insulin analogues |
| EP3831402A1 (de) | 2009-11-13 | 2021-06-09 | Sanofi-Aventis Deutschland GmbH | Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten, ein insulin und methionin |
| ES2965209T3 (es) | 2009-11-13 | 2024-04-11 | Sanofi Aventis Deutschland | Composición farmacéutica que comprende desPro36exendina-4(1-39)-Lys6-NH2 y metionina |
| EP2509995A4 (en) | 2009-12-11 | 2013-08-21 | Univ Case Western Reserve | INSULIN ANALOGUES COMPRISING CHLORINATED AMINO ACIDS |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| PT2611458T (pt) | 2010-08-30 | 2016-12-16 | Sanofi Aventis Deutschland | Utilização de ave0010 para o fabrico de um medicamento para o tratamento da diabetes mellitus tipo 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| AR087693A1 (es) | 2011-08-29 | 2014-04-09 | Sanofi Aventis Deutschland | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2 |
| AR087744A1 (es) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
| US9624287B2 (en) * | 2012-07-17 | 2017-04-18 | Case Western Reserve University | O-linked carbohydrate-modified insulin analogues |
| RU2019133674A (ru) | 2013-04-03 | 2020-05-20 | Санофи | Лечение сахарного диабета с помощью составов инсулинов длительного действия |
| AU2015204491B2 (en) | 2014-01-13 | 2021-01-07 | Thermalin Inc. | Rapid action insulin formulations and pharmaceutical delivery systems |
| WO2016001862A1 (en) * | 2014-07-04 | 2016-01-07 | Wockhardt Limited | Extended release formulations of insulins |
| EP3204410B1 (en) * | 2014-10-06 | 2021-01-20 | Case Western Reserve University | Biphasic single-chain insulin analogues |
| JP2017537065A (ja) * | 2014-10-20 | 2017-12-14 | ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ | 生物学的作用強度の高いハロゲン化インスリン類似体 |
| DK3229828T5 (da) | 2014-12-12 | 2024-10-14 | Sanofi Aventis Deutschland | Formulering med fast forhold mellem insulin glargin og lixisenatid |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| US20210214412A1 (en) * | 2018-04-16 | 2021-07-15 | University Of Utah Research Foundation | Glucose-responsive insulin |
| WO2020061554A1 (en) * | 2018-09-21 | 2020-03-26 | Case Western Reserve University | Site 2 single-chain insulin analogues |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5514646A (en) * | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
| US5534488A (en) * | 1993-08-13 | 1996-07-09 | Eli Lilly And Company | Insulin formulation |
| DE19825447A1 (de) * | 1998-06-06 | 1999-12-09 | Hoechst Marion Roussel De Gmbh | Neue Insulinanaloga mit erhöhter Zinkbildung |
| US7317000B2 (en) * | 2001-12-02 | 2008-01-08 | Novo Nordisk A/S | Glucose-dependent insulins |
| US8343914B2 (en) * | 2006-01-06 | 2013-01-01 | Case Western Reserve University | Fibrillation resistant proteins |
| EP2074140B8 (en) * | 2006-10-04 | 2015-10-28 | Case Western Reserve University | Fibrillation-resistant insulin and insulin analogues |
| US8993516B2 (en) * | 2008-04-14 | 2015-03-31 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
-
2011
- 2011-02-22 CN CN201180010561.4A patent/CN102770153B/zh not_active Expired - Fee Related
- 2011-02-22 EA EA201201164A patent/EA201201164A1/ru unknown
- 2011-02-22 US US13/580,656 patent/US20130085101A1/en not_active Abandoned
- 2011-02-22 CA CA2790495A patent/CA2790495A1/en not_active Abandoned
- 2011-02-22 JP JP2012554094A patent/JP2013520175A/ja not_active Withdrawn
- 2011-02-22 AU AU2011217761A patent/AU2011217761A1/en not_active Abandoned
- 2011-02-22 BR BR112012020481A patent/BR112012020481A2/pt not_active IP Right Cessation
- 2011-02-22 KR KR1020127021677A patent/KR20130043085A/ko not_active Application Discontinuation
- 2011-02-22 EP EP11745440.5A patent/EP2538966A4/en not_active Withdrawn
- 2011-02-22 MX MX2012009618A patent/MX2012009618A/es not_active Application Discontinuation
- 2011-02-22 WO PCT/US2011/025730 patent/WO2011103575A1/en active Application Filing
- 2011-02-22 SG SG2012052726A patent/SG183106A1/en unknown
-
2012
- 2012-07-17 ZA ZA2012/05315A patent/ZA201205315B/en unknown
-
2013
- 2013-05-06 HK HK13105402.6A patent/HK1178444A1/xx not_active IP Right Cessation
-
2017
- 2017-04-28 US US15/581,849 patent/US20170360895A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013520175A (ja) | 2013-06-06 |
| US20170360895A1 (en) | 2017-12-21 |
| SG183106A1 (en) | 2012-09-27 |
| CA2790495A1 (en) | 2011-08-25 |
| CN102770153A (zh) | 2012-11-07 |
| WO2011103575A1 (en) | 2011-08-25 |
| MX2012009618A (es) | 2013-02-26 |
| AU2011217761A1 (en) | 2012-08-02 |
| EP2538966A4 (en) | 2014-02-19 |
| EA201201164A1 (ru) | 2013-04-30 |
| CN102770153B (zh) | 2014-05-07 |
| EP2538966A1 (en) | 2013-01-02 |
| HK1178444A1 (en) | 2013-09-13 |
| US20130085101A1 (en) | 2013-04-04 |
| KR20130043085A (ko) | 2013-04-29 |
| ZA201205315B (en) | 2013-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012020481A2 (pt) | método para tratar um paciente, o método compreendendo administrar uma formulação farmacêutica contendo uma quantidade fisiologicamente efetiva de um análogo de insulina ou um sal fisiologicamente. | |
| MX2020011786A (es) | Oligomeros antisentido para tratamiento de afecciones y enfermedades. | |
| Teska et al. | Effects of phenol and meta-cresol depletion on insulin analog stability at physiological temperature | |
| MX2013004406A (es) | Tratamiento de diabetes mellitus usando inyecciones de insulina administradas con intervalos variables de inyeccion. | |
| EA033399B1 (ru) | Аналоги глюкагона с повышенной растворимостью и/или стабильностью и их применение | |
| TN2014000224A1 (en) | Glucagon analogues | |
| RU2011119988A (ru) | Композиции инсулинов длительного действия | |
| MX2018009100A (es) | Metodos para modular la flora intestinal. | |
| BR112012022223A2 (pt) | formulações de proteína concentrada e usos das mesmas | |
| RU2739037C3 (ru) | Композиция для контролируемой стимуляции яичников | |
| EA201692159A1 (ru) | Композиция для лечения диабета, содержащая конъюгат на основе аналога инсулина длительного действия и конъюгат на основе аналога инсулинотропного пептида длительного действия | |
| WO2007081824A3 (en) | Fibrillation resistant proteins | |
| NZ704275A (en) | Aav-mediated gene therapy for rpgr x-linked retinal degeneration | |
| BR112015022469A2 (pt) | peptídeo ou análogo seu, composição, método para melhorar um sinal ou sintoma, método para estimular o crescimento de células, método para produção de uma população de células, método para aumentar o número de células, método para redução em um indivíduo diabético da tolerância à glicose debilitada, método para a promoção de neuroproteção ou regeneração nervosa, método para a promoção da regeneração, método para a inibição de inflamação, composição farmacêutica e uso de um peptídeo ou análogo seu | |
| NZ603028A (en) | Tfpi inhibitors and methods of use | |
| RU2018107727A (ru) | Новые производные инсулина и их медицинские применения | |
| MY189079A (en) | Insulin analogues with chlorinated amino acids | |
| PH12015501931B1 (en) | Treatment of diabetes mellitus by long-acting formulations of insulins | |
| JP2016508123A5 (pt) | ||
| BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical | |
| IN2014CN04734A (pt) | ||
| EA201691420A1 (ru) | Композиции енолазы 1 (eno1) и их применение | |
| EP4269438A3 (en) | Oncolytic virus and method | |
| WO2011159758A4 (en) | Long lasting drug formulations | |
| WO2013010048A3 (en) | Non-standard insulin analogues |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |